Search
for
Sort by
Research 511–540 of 1000+
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
- JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Treatment of alopecia areata with JAK inhibitors
- PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
- Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, <i>InVitro</i>, and <i>In Silico</i> Studies
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
- Dermal papilla cells-conditioned medium attenuates oxidative stress-induced senescence via ferroptosis inhibition
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Qualitative study for finasteride detection in the prostate delivered by reversible inhibition of sperm under guidance – Prostate hair (RISUG-PH<sup>™</sup>) vas injectable implant
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’